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ABSTRACT
The GLOBAL (Global Landscape On Bactericidal Activity of Levoﬂoxacin) Surveillance programme
monitored antimicrobial susceptibility patterns of the key respiratory tract pathogens Streptococcus
pneumoniae, Haemophilus inﬂuenzae and Moraxella catarrhalis collected in Brazil during 1997–1998, 1999–
2000 and 2001–2002. Penicillin and azithromycin resistance among S. pneumoniae strains increased from
1997–1998, reaching 7.9% and 9.5%, respectively, in 2001–2002. Although decreasing by 4.9% since the
previous study, trimethoprim–sulphamethoxazole resistance remained high at 33.7%. Concurrent
resistance to penicillin, azithromycin and trimethoprim–sulphamethoxazole was seen in 2.9% of the
S. pneumoniae isolates collected. Levoﬂoxacin remained extremely active against S. pneumoniae, with
0.3% resistance reported in 1997–1998 and 0% resistance in 1999–2000 and 2001–2002. b-Lactamase
production in H. inﬂuenzae was > 10% in all three studies, with correspondingly high rates of ampicillin
resistance. Trimethoprim–sulphamethoxazole was the least active agent tested against H. inﬂuenzae, with
resistance rates of > 40% recorded in all three studies. All H. inﬂuenzae isolates were susceptible to
cefuroxime, ceftriaxone, azithromycin and levoﬂoxacin. Of the M. catarrhalis isolates, 98.0% in 1997–
1998, 98.0% in 1999–2000 and 81.8% in 2001–2002 were b-lactamase-positive. The continued high
prevalence of antimicrobial resistance in Brazil underscores the importance of current surveillance
initiatives. Levoﬂoxacin, a ﬂuoroquinolone prescribed widely for respiratory tract infections, continued
to show potent activity against key respiratory pathogens.
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INTRODUCTION
Antimicrobial resistance among pathogens com-
monly causing community-acquired respiratory
tract infections (RTIs) is a global problem,
although the prevalence of resistance varies con-
siderably by region as a result of numerous
variables, such as differences in prescribing prac-
tice, dosage of drug used, or (among Streptococcus
pneumoniae isolates) predominant serotype.
National and international surveillance pro-
grammes have played an important role in docu-
menting resistance patterns of the common
respiratory tract pathogens, S. pneumoniae, Haemo-
philus inﬂuenzae andMoraxella catarrhalis [1–3].
b-Lactam resistance among H. inﬂuenzae and
M. catarrhalis isolates, and resistance to b-lactams,
macrolides and trimethoprim–sulphamethoxaz-
ole among S. pneumoniae isolates, is encountered
commonly. Although the relationship between
resistance and clinical outcome is not always clear
for these drug classes, increasing problems con-
cerning therapy failures for RTIs may arise in the
future [4,5]. In Brazil, most RTIs are treated
empirically, perhaps exacerbated by a low rate of
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requests for microbiological tests by clinicians
and an inadequate number of microbiological
laboratories. For this reason, surveillance studies
provide an important tool for deﬁning regional
patterns of resistance and guiding empirical
antimicrobial therapeutic choice and the estab-
lishment of guidelines. The tendency of some
S. pneumoniae isolates to exhibit multidrug resist-
ance in recent years has created a need to ensure
that surveillance data sets are contemporary
[6,7]. Similarly, emerging resistance to amino-
penicillins in H. inﬂuenzae and M. catarrhalis
associated with plasmid-encoded b-lactamases,
and trimethoprim–sulphamethoxazole resistance
in H. inﬂuenzae, have heightened the need for
effective surveillance [6,7].
The introduction of ﬂuoroquinolones to treat
community-acquired RTIs, the ﬁrst of which was
levoﬂoxacin, has provided an important thera-
peutic alternative to b-lactams and macrolides,
especially in areas that exhibit a high prevalence
of resistance to these compounds. A recent study
in Brazil demonstrated that levoﬂoxacin retained
activity against most common RTI pathogens, and
showed that £ 1% of S. pneumoniae isolates were
ﬂuoroquinolone-resistant [6].
The GLOBAL (Global Landscape On Bacteri-
cidal Activity of Levoﬂoxacin) Surveillance pro-
gramme was initiated in 1997 to track
susceptibility to levoﬂoxacin in countries where
this respiratory ﬂuoroquinolone is used, especi-
ally in the treatment of community-acquired RTIs.
The present report provides a longitudinal view
of antimicrobial susceptibility among the key
respiratory pathogens, S. pneumoniae, H. inﬂuenzae
and M. catarrhalis, isolated from patient speci-
mens in Brazil. Isolates were collected at Brazilian
medical centres over three successive periods,
1997–1998, 1999–2000 and 2001–2002, thereby
providing an overview on the evolution of resist-
ance trends during these 3 years.
MATERIALS AND METHODS
Organism collection
Isolates were collected during 1997–1998, 1999–2000 and
2001–2002 as part of the biannual GLOBAL Surveillance
Initiative. In total, 1122 S. pneumoniae (1997–1998, 359; 1999–
2000, 448; 2001–2002, 315), 827 H. inﬂuenzae (1997–1998, 219;
1999–2000, 274; 2001–2002, 334) and 123 M. catarrhalis (1997–
1998, 52; 1999–2000, 49; 2001–2002, 22) strains were isolated
from patient specimens in Brazilian hospital laboratories
(1997–1998, ﬁve sites; 1999–2000, six sites; 2001–2002, four
sites). Isolates were collected from the upper and lower
respiratory tract (620 S. pneumoniae, 656 H. inﬂuenzae, 116
M. catarrhalis), blood (264 S. pneumoniae, 42 H. inﬂuenzae, one
M. catarrhalis), cerebrospinal ﬂuid (ten S. pneumoniae, ﬁve
H. inﬂuenzae) and other or unknown (228 S. pneumoniae, 124
H. inﬂuenzae, six M. catarrhalis) specimen sources. All isolates
were transported to the central laboratory of Focus Technol-
ogies (Herndon, VA, USA), where they were subcultured on
to blood agar (S. pneumoniae and M. catarrhalis) or chocolate
agar (H. inﬂuenzae), and re-identiﬁed using standard
methods.
Antimicrobial susceptibility testing
In-vitro antimicrobial susceptibilities of all isolates were
determined using standardised broth microdilution methodo-
logy [8] and Sensititre panels containing dried antimicrobials
(TREK Diagnostic Systems, East Grinstead, UK). Isolates were
tested against penicillin (S. pneumoniae only), and ampicillin
(H. inﬂuenzae andM. catarrhalis only), amoxycillin–clavulanate,
cefuroxime, ceftriaxone, azithromycin, clarithromycin, levoﬂ-
oxacin, trimethoprim–sulphamethoxazole and vancomycin
(S. pneumoniae only), over a range of concentrations.
RESULTS
S. pneumoniae
The antimicrobial susceptibilities of 315 isolates of
S. pneumoniae collected in Brazil during 2001–2002
are shown in Table 1 in comparison with the data
from previous surveys. Of the most recent iso-
lates, 7.9% were penicillin-resistant and 22.2%
were penicillin-intermediate. For this same per-
iod, rates of resistance in S. pneumoniae to other
drugs tested were 9.5% for both azithromycin
and clarithromycin, 33.7% for trimethoprim–sul-
phamethoxazole, and 11.7% for cefuroxime. All
pneumococcal isolates were susceptible to levoﬂ-
oxacin, ceftriaxone and vancomycin. There was a
high degree of cross-resistance between penicillin
and azithromycin or trimethoprim–sulphameth-
oxazole. Penicillin-susceptible isolates of S. pneu-
moniae (2001–2002) showed 4.5% resistance
to azithromycin and 19.5% resistance to trimeth-
oprim–sulphamethoxazole (data not shown).
However, penicillin-resistant isolates showed
36.0% resistance to azithromycin and 100%
resistance to trimethoprim–sulphamethoxazole
(data not shown).
Penicillin susceptibility in 2001–2002 (69.8%)
decreased in comparison with previous periods
(77.2% in 1997–1998 and 1999–2000) (Table 1).
Although penicillin resistance rates ﬂuctuated
between the surveys because of increased vari-
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ation in the intermediate isolates, the 2001–2002
resistance rate (7.9%) was an increase. The same
phenomenon was detected for resistance to azith-
romycin and clarithromycin, with 9.5% azithro-
mycin resistance in 2001–2002 compared with
4.2% in 1997–1998. A 5.0% increase in penicillin
resistance and a 4.8% increase in azithromycin
resistance were detected between 1999–2000 and
the present study. Resistance to trimethoprim–
sulphamethoxazole remained high (33.7%) in
2001–2002. However, compared to 1999–2000,
there was a 4.9% decrease in trimethoprim–
sulphamethoxazole resistance. This decrease
followed a 15.2% increase in trimethoprim–sul-
phamethoxazole resistance between 1997–1998
and 1999–2000. Levoﬂoxacin resistance was very
low or not detected in all three study periods,
with 0.3% resistance in 1997–1998 and 0% resist-
ance in both 1999–2000 and 2001–2002.
Multidrug-resistant (MDR) phenotypes among
S. pneumoniae isolates collected in 1997–1998,
1999–2000 and 2001–2002 are shown in Table 2.
Resistance to penicillin, azithromycin and trim-
ethoprim–sulphamethoxazole was the only MDR
phenotype encountered, increasing steadily from
1997–1998 (0.3%) and 1999–2000 (0.9%) to 2001–
2002 (2.9%). The increase in MDR phenotype
occurred concurrently with the increased resist-
ance rates observed for each of these antimicro-
bial agents separately.
H. inﬂuenzae
b-Lactamase production among H. inﬂuenzae
isolates was 11.0% in 1997–1998, 10.6% in 1999–
2000 and 14.7% in 2001–2002 (data not shown).
Antimicrobial susceptibility among H. inﬂuenzae
isolates collected during 1997–1998, 1999–2000
and 2001–2002 is shown in Table 3. There was a
1.0% increase in ampicillin resistance from
1997–1998 to 1999–2000, and a 4.1% increase in
ampicillin resistance from 1999–2000 to 2001–
2002. Clarithromycin showed a slight increase
(0.5%) in the resistance rate from 1999–2000 to
2001–2002. However, the clarithromycin-interme-
diate rate showed a marked variance between the
three study periods, with a decrease of 5.2% from
1997–1998 to 1999–2000, followed by an increase
of 10.3% from 1999–2000 to 2001–2002. Trimeth-
oprim–sulphamethoxazole resistance increased
by 2.7% from 1999–2000 to 2001–2002. All isolates
were susceptible to azithromycin, ceftriaxone,
cefuroxime and levoﬂoxacin in all three study
periods.
Table 1. Antimicrobial susceptibility among Streptococcus pneumoniae isolates collected during 1997–1998a, 1999–2000b and
2001–2002c
Antimicrobial Study year
MIC90
(mg/L) % Susceptibled
% Change from
previous year % Intermediated
% Change from
previous year % Resistantd
% Change from
previous year
Amoxycillin-clavulanate 1997–1998 0.06 99.7 0.3 0
1999–2000 0.06 100 0.3 0 ) 0.3 0 0
2001–2002 1 99.4 ) 0.6 0.3 0.3 0.3 0.3
Azithromycin 1997–1998 0.06 95.3 0.6 4.2
1999–2000 0.06 94.9 ) 0.4 0.4 ) 0.2 4.7 0.5
2001–2002 0.25 90.2 ) 4.7 0.3 ) 0.1 9.5 4.8
Ceftriaxone 1997–1998 0.12 98.6 1.4 0
1999–2000 0.12 99.6 1.0 0.4 ) 1.0 0 0
2001–2002 0.5 99.4 ) 0.2 0.6 ) 0.2 0 0
Cefuroxime 1997–1998 0.5 92.5 2.2 5.3
1999–2000 0.5 91.5 ) 1.0 3.1 0.9 5.4 0.1
2001–2002 4 87.3 ) 4.2 1.0 ) 2.2 11.7 6.4
Clarithromycin 1997–1998 0.03 95.3 0 4.7
1999–2000 0.03 94.9 ) 0.4 0.2 0.2 4.9 0.2
2001–2002 0.25 90.2 ) 4.7 0.3 0.1 9.5 4.6
Levoﬂoxacin 1997–1998 1 99.7 0 0.3
1999–2000 1 100 0.3 0 0 0 ) 0.3
2001–2002 1 100 0 0 0 0 0
Penicillin 1997–1998 0.25 77.2 18.7 4.2
1999–2000 0.25 77.2 0 19.9 1.2 2.9 ) 1.3
2001–2002 1 69.8 ) 7.3 22.2 2.4 7.9 5.0
Trimethoprim–sulphamethoxazole 1997–1998 4 48.2 28.4 23.4
1999–2000 >4 44.9 ) 3.3 16.5 ) 11.9 38.6 15.2
2001–2002 4 42.2 ) 2.6 24.1 7.6 33.7 ) 4.9
Vancomycin 1997–1998 0.5 100 0 0
1999–2000 0.5 100 0 0 0 0 0
2001–2002 0.5 100 (0) 0 0 0 0
aThree hundred and ﬁfty-nine isolates were collected during 1997–1998.
bFour hundred and forty-eight isolates were collected during 1999–2000.
cThree hundred and ﬁfteen isolates were collected during 2001–2002.
dNational Committee for Clinical Laboratory Standards published breakpoints were used [9].
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M. catarrhalis
b-Lactamase production among M. catarrhalis
isolates was 98.0% in 1997–1998, 98.0% in 1999–
2000, and 81.8% in 2001–2002 (data not shown).
Antimicrobial susceptibility among M. catarrhalis
isolates collected during 1997–1998, 1999–2000
and 2001–2002 is presented in Table 4. As there
are no published National Committee for Clinical
Laboratory Standards breakpoints for M. catarrh-
alis, results are shown as MIC90s. There was an
increase in the MIC90 of ampicillin from 4 mg ⁄L
in 1999–2000 to 8 mg ⁄L in 2001–2002. The levo-
ﬂoxacin MIC90 remained the same (0.03 mg ⁄L)
between 1999–2000 and 2001–2002, although it
was recorded as 0.06 mg ⁄L in 1997–1998.
DISCUSSION
Penicillin and macrolides have been traditionally
the main therapies for community-acquired
RTIs. For S. pneumoniae, the predominant agent
causing community-acquired RTIs, 30.1% of
isolates collected in Brazil during 2001–2002
were penicillin-non-susceptible. The proportion
of isolates resistant to penicillin has increased
since 1997–1998 to 7.9%. These are the isolates
more likely to be multiply-resistant and result in
Table 2. Multidrug-resistant phenotypes among Streptococcus pneumoniae isolates collected in 1997–1998, 1999–2000 and
2001–2002
Phenotype
1997–1998 1999–2000
% Change from
the previous study
2001–2002
% Change from
the previous studyn % n % n %
Pan-susceptible 265 73.8 268 59.8 ) 14.0 198 62.9 3.1
Trimethoprim–sulphamethoxazole 65 18.1 150 33.5 15.4 71 22.5 ) 11.0
Penicillin 5 1.4 0 0 ) 1.4 0 0 0
Azithromycin 4 1.1 7 1.6 0.5 11 3.5 1.9
Levoﬂoxacin 1 0.3 0 0 ) 0.3 0 0 0
Azithromycin,
trimethoprim–sulphamethoxazole
9 2.5 10 2.2 ) 0.3 10 3.2 1.0
Penicillin,
trimethoprim–sulphamethoxazole
8 2.2 9 2.0 ) 0.2 16 5.1 3.1
Azithromycin,
penicillin,
trimethoprim–sulphamethoxazole
2 0.3 4 0.9 0.6 9 2.9 2.0
Table 3. Antimicrobial susceptibility among Haemophilus inﬂuenzae isolates collected during 1997–1998a, 1999–2000b and
2001–2002c
Antimicrobial Study year
MIC90
(mg ⁄L) % Susceptibled
% Change from
previous year % Intermediated
% Change from
previous year % Resistantd
% Change from
previous year
Amoxycillin–clavulanate 1997–1998 1 100 0 0
1999–2000 1 99.6 ) 0.4 0 0 0.4 0.4
2001–2002 1 100 0.4 0 0 0 ) 0.4
Ampicillin 1997–1998 2 89.0 1.4 9.6
1999–2000 8 89.1 0.1 0.4 ) 0.6 10.6 1.0
2001–2002 >8 85.3 ) 3.7 0 ) 0.4 14.7 4.1
Azithromycin 1997–1998 2 100 0 0
1999–2000 2 100 0 0 0 0 0
2001–2002 2 100 0 0 0 0 0
Ceftriaxone 1997–1998 0.03 100 0 0
1999–2000 £0.015 100 0 0 0 0 0
2001–2002 £0.015 100 0 0 0 0 0
Cefuroxime 1997–1998 2 100 0 0
1999–2000 1 100 0 0 0 0 0
2001–2002 2 99.4 ) 0.6 0.6 0.6 0 0
Clarithromycin 1997–1998 8 92.2 7.8 0
1999–2000 8 97.1 4.9 2.6 ) 5.2 0.4 0.4
2001–2002 16 86.2 ) 10.9 12.9 10.3 0.9 0.5
Levoﬂoxacin 1997–1998 0.015 100 0 0
1999–2000 0.015 100 0 0 0 0 0
2001–2002 0.015 100 0 0 0 0 0
Trimethoprim–sulphamethoxazole 1997–1998 >4 47.0 7.8 45.2
1999–2000 >4 50.4 3.4 9.5 1.7 40.1 ) 5.1
2001–2002 >4 53.0 2.6 4.2 ) 5.3 42.8 2.7
aTwo hundred and nineteen isolates were collected during 1997–1998.
bTwo hundred and seventy-four isolates were collected during 1999–2000.
cThree hundred and thirty-four isolates were collected during 2001–2002.
dNational Committee for Clinical Laboratory Standards breakpoints were used [9].
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clinical failure. Azithromycin and trimethoprim–
sulphamethoxazole resistance rates among
S. pneumoniae isolates in 2001–2002 were 9.5%
and 33.7%, respectively. As with penicillin, the
prevalence of macrolide resistance in 2001–2002
represents a large increase over that recorded in
1999–2000. Importantly, these resistance pheno-
types were not occurring alone; there was a high
degree of cross-resistance between penicillin and
azithromycin or trimethoprim–sulphamethoxaz-
ole. Trimethoprim–sulphamethoxazole resistance
was a signiﬁcant problem, with rates of > 20%
reported in all three study periods. Levoﬂoxacin
resistance among S. pneumoniae isolates was
exceedingly low in all three study periods, with
0.3% resistance in 1997–1998 and 0% resistance in
both 1999–2000 and 2001–2002.
b-Lactamase production among H. inﬂuenzae
isolates was > 10% in all three study periods, with
corresponding levels of ampicillin resistance.
Resistance to trimethoprim–sulphamethoxazole
was > 40% in all three studies. While clarithro-
mycin resistance was relatively rare in all three
studies (< 1%), the prevalence of clarithromycin-
intermediate isolates increased by 10.3% between
1999–2000 (2.6%) and 2001–2002 (12.9%). Despite
these high rates of resistance and intermediate
resistance, all isolates were susceptible to levo-
ﬂoxacin, cefuroxime and ceftriaxone.
M. catarrhalis continued to exhibit high rates of
b-lactamase production, with > 80% of isolates
encountered in each study period being b-lacta-
mase-positive. This current picture of resistance
may inﬂuence therapeutic choices, especially with
regard to agents for oral use.
Although increasing, penicillin and macrolide
resistance among S. pneumoniae isolates in Brazil
is still low compared to various other countries
[10]. However, the epidemiological pattern found
in Brazil follows that found in various other
countries, with b-lactam, macrolide and tri-
methoprim–sulphamethoxazole resistance being
more prevalent among penicillin-intermediate
and -resistant strains. The low resistance rates
among S. pneumoniae isolates for levoﬂoxacin and
vancomycin are similar to those reported in
previous studies [7,10,11].
There is no doubt about the worldwide
importance of MDR S. pneumoniae, including the
most prevalent phenotypes (resistance to penicil-
lin, macrolides and trimethoprim–sulphameth-
oxazole) [10,11]. The MDR S. pneumoniae pattern
observed in the present study increased in each
survey period, with rates of 0.3% in 1997–1998,
0.9% in 1999–2000, and 2.9% in 2001–2002. The
only MDR phenotype detected in all three study
periods in Brazil was resistance to penicillin,
azithromycin and trimethoprim–sulphameth-
oxazole. This is in accordance with the increased
resistance rates found for each of these antimicro-
bials separately. There was an overall absence of
resistance to levoﬂoxacin and third-generation
cephalosporins among these MDR isolates, which
suggests that resistance to levoﬂoxacin may occur
independently of penicillin, macrolide or trimeth-
oprim–sulphamethoxazole resistance. This is sup-
ported by other studies in Brazil [6,12]andbyother
international studies [10,11]. Although there are
other MDR phenotypes with resistance to other
antimicrobial classes, including ﬂuoroquinolones,
this is still a rare event in Brazil, being most
prevalent in Asian countries such as Hong Kong
and South Korea, which often show levoﬂoxacin
resistance rates exceeding 2% [13]. This study
found low rates of levoﬂoxacin resistance in all
three study periods in Brazil, thereby demonstra-
ting that levoﬂoxacin remains extremely active
despite its increasing use locally and worldwide.
Appropriate antimicrobial use is important to help
prevent the emergence and dissemination of ﬂuor-
oquinolone-resistant S. pneumoniae.
Table 4. Antimicrobial susceptibility among Moraxella
catarrhalis isolates collected during 1997–1998a, 1999–
2000b and 2001–2002c
Antimicrobial Study year MIC90 (mg/L)
Amoxycillin–clavulanate 1997–1998 0.25
1999–2000 0.25
2001–2002 0.25
Ampicillin 1997–1998 >8
1999–2000 4
2001–2002 8
Azithromycin 1997–1998 £0.03
1999–2000 £0.03
2001–2002 0.03
Ceftriaxone 1997–1998 0.5
1999–2000 0.5
2001–2002 0.5
Cefuroxime 1997–1998 2
1999–2000 2
2001–2002 2
Clarithromycin 1997–1998 0.12
1999–2000 0.12
2001–2002 0.12
Levoﬂoxacin 1997–1998 0.06
1999–2000 0.03
2001–2002 0.03
Trimethoprim–sulphamethoxazole 1997–1998 0.5
1999–2000 0.5
2001–2002 0.5
aFifty-two isolates were collected during 1997–1998.
bForty-nine isolates were collected during 1999–2000.
cTwenty-two isolates were collected during 2001–2002.
Mendes et al. Susceptibility of respiratory pathogens in Brazil 525
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 521–526
Antimicrobial resistance surveillance pro-
grammes are valuable tools and provide import-
ant information on bacterial resistance trends in
terms of either geographical location or disease
type in community and hospital settings [14,15].
However, surveillance programmes are limited in
their ability to answer all relevant clinical and
microbiological questions for all world regions,
particularly if they present point estimates of
prevalence. Thus, efforts must be made to devel-
op surveillance programmes with longitudinal
approaches and ⁄ or geographical references, in
order to provide a better understanding of the
mechanisms of bacterial resistance and to reﬁne
clinical decision tools locally. The GLOBAL Sur-
veillance programme offers a longitudinal view of
three distinct study periods (1997–1998, 1999–
2000, and 2001–2002) on antimicrobial suscepti-
bility among key respiratory pathogens in Brazil,
and hopefully will enable clinical decisions to be
made using an evidence-based approach.
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